Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImageneBio ( (IMA) ) has shared an update.
On March 12, 2026, ImageneBio, Inc. agreed to a mutual separation with Erin Butler, its Senior Vice President, Finance & Administration and Principal Accounting Officer, effective March 20, 2026, with Butler expected to receive severance benefits under a prior agreement. The board simultaneously appointed Bob Lally, the company’s Senior Vice President, Finance & Operations and a veteran finance executive from Ikena Oncology, Prevail Therapeutics, and Arsanis, as Principal Accounting Officer, signaling continuity in financial leadership without new compensation arrangements or related-party concerns.
The most recent analyst rating on (IMA) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on ImageneBio stock, see the IMA Stock Forecast page.
Spark’s Take on IMA Stock
According to Spark, TipRanks’ AI Analyst, IMA is a Neutral.
The score is held down primarily by weak financial performance (no current revenue, large losses, and ongoing cash burn). Technicals add further pressure due to a clear downtrend, while valuation provides limited support because profitability is negative and there is no dividend.
To see Spark’s full report on IMA stock, click here.
More about ImageneBio
ImageneBio, Inc. operates in the biotechnology and life sciences sector, evolving from its predecessor Ikena Oncology, Inc. The company focuses on developing therapeutic innovations and maintains a finance and operations organization with executives experienced in biotech and pharmaceutical ventures, underscoring its emphasis on rigorous financial oversight and operational discipline.
Average Trading Volume: 43,631
Technical Sentiment Signal: Sell
Current Market Cap: $69.35M
See more data about IMA stock on TipRanks’ Stock Analysis page.